Novanta Inc.
NASDAQ•NOVT
CEO: Mr. Matthijs Glastra
Sector: Technology
Industry: Hardware, Equipment & Parts
Listing Date: 1999-03-24
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
Contact Information
Market Cap
$4.87B
P/E (TTM)
97.0
27.2
Dividend Yield
--
52W High
$149.95
52W Low
$98.27
52W Range
Rank40Top 42.0%
4.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$258.35M+0.00%
4-Quarter Trend
EPS
$0.46+0.00%
4-Quarter Trend
FCF
$5.13M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenue reached $980.6M, marking a 3.3% increase; Medical Solutions revenue grew 4.6% to $479.8M.
Major Equity Financing Closed Issued 6.50% tangible equity units, securing $613.1M net proceeds in November 2025 to bolster liquidity position.
Backlog Signals Future Demand Consolidated backlog increased to $481.2M as of year-end 2025, up from $445.5M in 2024, indicating order strength.
Automation Revenue Rises Automation Enabling Technologies segment revenue increased 2.1% to $500.8M, driven by robotics and automation product sales.
Risk Factors
Operating Income Declined Operating income fell 15.0% to $94.0M in 2025, driven by higher SG&A and restructuring/acquisition related costs.
Customer Concentration Exposure Top two OEM customers represented 23% of 2025 consolidated revenue, posing concentration risk if orders significantly reduce.
Regulatory Complexity High Subject to extensive and dynamic medical device regulations across US, EU, and UK, increasing compliance complexity and costs.
Margin Pressure Evident Automation segment gross margin slightly decreased due to higher tariff costs and temporary increases from regional manufacturing strategy.
Outlook
Medical Sales Mix Focus Strategy centers on improving business mix to increase medical sales percentage of total revenue via new product introductions.
Capital Structure Management Debt level stands at $259.6M total; $850.0M unused borrowing capacity available under the revolving credit facility.
Operational Efficiency Improvement Plans include strengthening operational performance via lean manufacturing and advancing strategic sourcing initiatives across major sites.
Technology Acquisition Strategy Will continue broadening portfolio through investment in new product development and pursuing complementary medical technology acquisitions.
Peer Comparison
Revenue (TTM)
$5.30B
$4.13B
$3.71B
Gross Margin (Latest Quarter)
102.1%
65.5%
58.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VICR | $8.19B | 69.4 | 18.7% | 1.6% |
| ESE | $7.08B | 23.2 | 21.3% | 7.9% |
| VNT | $5.74B | 14.0 | 34.0% | 48.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.4%
Moderate Growth
4Q Net Income CAGR
-6.3%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 4, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data